Insulet (Nasdaq:PODD) today shared new clinical evidence for its first fully closed-loop automated insulin delivery system for type 2 diabetes. The maker of the Omnipod 5 — the world’s first available tubeless, wearable, automated insulin delivery system — said during a 2025 Investor Day event that it plans to bring its first fully closed-loop system […]
Insulet
Insulet stock rises before hours on Street-beating Q4, 31% sales growth
Insulet (Nasdaq:PODD) shares got a boost today on fourth-quarter results that came in ahead of the consensus forecast. Shares of PODD ticked up more than 8% to $266.10 apiece in morning trading today. The Acton, Massachusetts–based automated insulin delivery technology developer reported profits of $101.6 million. That equals $1.44 per share on sales of $783.8 […]
Insulet launches Omnipod 5, Omnipod Discover in the Middle East
Insulet (Nasdaq:PODD) announced today that it launched its Omnipod 5 and Omnipod Discover offerings in the Middle East. The company made its automated insulin delivery system available in Saudi Arabia, Kuwait, Qatar and the United Arab Emirates (UAE). Omnipod 5 became the world’s first available tubeless, wearable, automated insulin delivery system when it received FDA […]
Insulet debuts at CES to showcase automated insulin delivery tech
Insulet (Nasdaq:PODD) announced today that it debuted at the Consumer Electronics Show (CES) 2026 in Las Vegas. The debut includes the showcasing of the company’s automated insulin delivery (AID) technology. Acton, Massachusetts-based Insulet said its presence at CES features an immersive booth experience, expert panel session and media demonstrations. Insulet said the company’s CES debut […]
The top diabetes tech stories of 2025
As the year comes to a close, it’s time to look back at the numerous innovations across the diabetes technology industry in 2025. Once again, continuous glucose monitors (CGMs) and automated insulin delivery systems took most of the headlines, as the leaders in the space keep building on their platforms while challengers continue to enter […]
Insulet expands Pod recycling program across U.S.
Insulet (Nasdaq:PODD) announced today that it expanded its U.S. Pod recycling program, now making it available to all U.S. customers. The Pod recycling program, offered at no cost to customers, enables users to request a recycling kit online. This allows them to return their used Omnipods. Insulet then decontaminates the returned Pods before transporting them […]
Insulet appoints first chief corporate affairs officer
Insulet (Nasdaq:PODD) announced today that it appointed Cristal Downing as its new chief corporate affairs officer, effective today. In the newly created role at the automated insulin delivery system developer, Downing will build and lead a corporate affairs function aimed at strengthening Insulet’s corporate reputation, advancing business priorities, catalyzing customer value and deepening engagement with […]
Insulet wins FDA clearance for Omnipod 5 algorithm enhancements
Insulet (Nasdaq:PODD) announced today that it received FDA 510(k) clearance for new enhancements to its Omnipod 5 system. The Acton, Massachusetts–based company said the updates to its tubeless, wearable automated insulin delivery patch pump’s algorithm include a new benchmark in tubeless diabetes technology with a lower, 100 mg/dL target glucose option. It also delivers a […]
Insulet makes Omnipod 5 available with Dexcom G7 15 Day CGM
Insulet (Nasdaq:PODD) today announced immediate compatibility between its Omnipod 5 system and the Dexcom (Nasdaq:DXCM) G7 15 Day CGM. Acton, Massachusetts-based Insulet, which has paired its pumps with previous versions of Dexcom continuous glucose monitors (CGMs), has offered Omnipod 5 with the initial version of G7 since early 2024. However, Dexcom received FDA clearance for people […]
Insulet CEO Ashley McEvoy lays out plans for Omnipod 6, innovation roadmap
Insulet (Nasdaq:PODD) today hosted its Investor Day, led by President and CEO Ashley McEvoy, laying out the future for the insulin pump maker. McEvoy, who assumed the corner office six months ago, has recently spoken about the company’s use of artificial intelligence to advance its automated insulin delivery (AID) offerings, while competition continues to heat […]
